We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$758M
1-Year Est. Return
124.8%
This Fund
S&P 500
This Quarter
Est. Return
+15.57%
1 Year Est. Return
+124.8%
3 Year Est. Return
+486.05%
5 Year Est. Return
+742.19%
10 Year Est. Return
+62,231.09%
AUM
$758M
AUM Growth
+$493K
(+0.07%)
Cap. Flow
-$40.4M
Cap. Flow
% of AUM
-5.33%
Top 10 Holdings %
Top 10 Hldgs %
61.52%
Holding
62
New
8
Increased
18
Reduced
13
Closed
9
Top Buys
| 1 |
UroGen Pharma
URGN
|
+$23.3M |
| 2 |
Disc Medicine
IRON
|
+$15.3M |
| 3 |
Perspective Therapeutics
CATX
|
+$14.7M |
| 4 |
MeiraGTx Holdings
MGTX
|
+$13.2M |
| 5 |
Q32 Bio
QTTB
|
+$4.95M |
Top Sells
| 1 |
Harrow
HROW
|
+$47.2M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$20.1M |
| 3 |
CG Oncology
CGON
|
+$17.9M |
| 4 |
Alkermes
ALKS
|
+$13.7M |
| 5 |
Ocular Therapeutix
OCUL
|
+$9.48M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Relmada Therapeutics
RLMD
$652M
| $6.51M | 0.86% |
935,000
| – | – |
|
|
27
CG Oncology
CGON
$6.33B
| $6.42M | 0.85% |
94,800
-315,200
| -77% | -$17.9M |
|
|
JBIO
28
Jade Biosciences
JBIO
$1.3B
| $6.01M | 0.79% |
427,608
| – | – |
|
|
29
Ocular Therapeutix
OCUL
$2.12B
| $5.08M | 0.67% |
600,000
-995,000
| -62% | -$9.48M |
|
|
ASRT
30
DELISTED
Assertio
ASRT
| $5.06M | 0.67% |
265,707
-19,293
| -7% | -$237K |
|
31
Editas Medicine
EDIT
$485M
| $4.76M | 0.63% |
+1,926,997
| New | +$4.08M |
|
32
Sutro Biopharma
STRO
$431M
| $4.75M | 0.63% |
190,671
| – | – |
|
33
Journey Medical
DERM
$196M
| $4.5M | 0.59% |
960,000
-15,000
| -2% | -$116K |
|
34
Voyager Therapeutics
VYGR
$191M
| $4.44M | 0.59% |
1,150,000
-46,904
| -4% | -$185K |
|
35
Trevi Therapeutics
TRVI
$2.54B
| $4.12M | 0.54% |
345,100
| – | – |
|
|
TECX
36
Tectonic Therapeutic
TECX
$657M
| $3.8M | 0.5% |
123,000
-91,747
| -43% | -$2.26M |
|
37
Cabaletta Bio
CABA
$435M
| $3.71M | 0.49% |
1,380,000
+480,000
| +53% | +$1.33M |
|
38
Biodesix
BDSX
$219M
| $3.45M | 0.46% |
+238,047
| New | +$2.95M |
|
39
Rocket Pharmaceuticals
RCKT
$397M
| $3.42M | 0.45% |
955,000
| – | – |
|
40
Zentalis Pharmaceuticals
ZNTL
$340M
| $3.31M | 0.44% |
1,412,656
+11,750
| +0.8% | +$30.3K |
|
41
Intellia Therapeutics
NTLA
$1.86B
| $3.14M | 0.41% |
+245,000
| New | +$3.12M |
|
42
Fortress Biotech
FBIO
$124M
| $2.91M | 0.38% |
1,042,000
-48,000
| -4% | -$163K |
|
|
IRD
43
Opus Genetics
IRD
$294M
| $2.25M | 0.3% |
1,120,000
| – | – |
|
44
Rigel Pharmaceuticals
RIGL
$762M
| $1.89M | 0.25% |
70,000
| – | – |
|
45
Atea Pharmaceuticals
AVIR
$376M
| $1.74M | 0.23% |
322,600
+142,785
| +79% | +$656K |
|
46
Lyell Immunopharma
LYEL
$313M
| $1.59M | 0.21% |
+79,097
| New | +$1.85M |
|
47
Enanta Pharmaceuticals
ENTA
$381M
| $1.58M | 0.21% |
125,000
+50,000
| +67% | +$670K |
|
48
NextCure
NXTC
$23.8M
| $1.51M | 0.2% |
+141,181
| New | +$1.72M |
|
49
4D Molecular Therapeutics
FDMT
$612M
| $1.05M | 0.14% |
+112,291
| New | +$977K |
|
50
Protalix BioTherapeutics
PLX
$186M
| $738K | 0.1% |
340,000
-2,138,176
| -86% | -$5.31M |
|
Similar funds
WCFA
SIG
GWM
IAS
TVAMP
RFM
MWA
CFS